10:15:20 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-02-21 Bokslutskommuniké 2023
2023-11-13 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-07-03 X-dag ordinarie utdelning IRRAS 0.00 SEK
2023-06-30 Årsstämma 2023
2023-05-17 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning IRRAS 0.00 SEK
2022-05-24 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-07-15 Extra Bolagsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-04-29 X-dag ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-29 X-dag ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 Årsstämma 2020
2020-03-02 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-15 X-dag ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-14 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-06-04 X-dag ordinarie utdelning IRRAS 0.00 SEK
2018-05-29 Kvartalsrapport 2018-Q1


ListaSmall Cap Stockholm
IRRAS är verksamt inom medicinteknik. Bolaget är inriktade mot att utveckla lösningar för kirurgiska ingrepp vid hjärnsjukdomar. Bolaget har för närvarande utvecklat en teknologisk plattform som fokuserar på hantering av en rad delmoment vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Bolaget har sitt huvudkontor i Stockholm.
2023-08-24 07:45:00

Stockholm, Sweden(24 August 2023) - This statement is made by the Independent Bid Committee (the "Committee") of IRRAS AB (publ) (the "Company" or "IRRAS"). The Committee consists of the Board Members Anita Tollstadius (chairperson) and Catherine Gilmore-Lawless.

The Offer

On 30 June 2023, Legacy Capital, Spetses, Bacara Holdings, Lexington Holding Assets, Kleanthis G. Xanthopoulos, Panormos, Philippe Audi, and Nicolas Murat (the "BidConsortium"), through IR Holding Bidco Inc. ("IR Holding"), announced a public offer to acquire all shares in IRRAS for SEK 0.18 in cash per share (the "Offer").

On 21 August 2023, IR Holding announced that the Offer had been accepted by shareholders holding 20.9 percent of the total number of shares and votes in IRRAS. Members of the Bid Consortium already owned 59.5 percent of the total number of shares and votes in IRRAS prior to the announcement of the Offer. In total, the number of shares tendered in the Offer and the shares already owned by the members of the Bid Consortium equal 80.4 percent of the total number of shares and votes in IRRAS. As set out in IRHolding's press release announcing the Offer and the offer document regarding the Offer, completion of the Offer is conditional upon,inter alia, the Offer being accepted to such extent that IR Holding becomes the owner of more than 90 percent of the shares in IRRAS.

On 21 August 2023, IR Holding also announced an extension of the acceptance period until 1 September 2023 to allow shareholders that have not yet responded to the Offer an opportunity to do so. Further, IR Holding announced that it will not increase the price per share in the Offer.

The Independent Bid Committee's Consideration of the Latest Announcement by IR Holding

The Committee reiterates that IRRAS is in immediate need of funding. The Company's current cash on hand results from a short-term loan facility from Bacara Holdings, the Company's second largest shareholder, which is also part of the Bid Consortium. There is an imminent risk that the Company will default on the short-term loan agreement, which is due on 15 September 2023, and become insolvent, and this risk has increased due to the announced extension of the Offer acceptance period. At the current time, no known alternative financing options are available that would provide IRRAS needed capital to repay the loan facility.

Under the short-term loan facility, the Company has pledged its patents and shares in its United States subsidiary, IRRAS USA Inc., to Bacara Holdings as collateral. The terms of the loan also outline that IRRAS USA Inc. will guarantee all remaining obligations of IRRAS AB in exchange for IRRAS AB entering into a license agreement with IRRAS USA Inc. (which would be collaterally assigned to the lender) that will grant IRRAS USA Inc. an exclusive, royalty-free, fully-paid, irrevocable, perpetual license to all of IRRAS' intellectual property everywhere in the world other than Sweden, Denmark, Norway, and Finland.

In order to prepare for the possibility that the Offer will not be approved by 90 percent of IRRAS' shareholders by the expiration of the extended acceptance period on 1 September 2023, the Company has continued to seek other potential investors that would be willing to lead an equity financing or secure a rights issue to provide IRRAS sufficient funds to repay its current loan obligation and continue its operations for a sufficient period of time that would allow other long-term financing options to be fully explored.

As a thorough process to identify financing alternatives has been underway since the beginning of this year with no concrete alternatives identified other than the current Offer, the Committee would like to stress that the chances of securing such alternative financing are low for the Company.

Based on these factors, the Committee reiterates its recommendation to the shareholders of IRRAS to accept the Offer.


This statement by the Independent Bid Committee is governed by and shall be interpreted in accordance with Swedish law. Disputes arising from this statement shall be settled exclusively by a Swedish court.

Stockholm, 24 August 2023

The Independent Bid Committee for IRRAS AB (publ)

For additional information, please contact:

Anita Tollstadius

Chairperson of the Independent Bid Committee for IRRAS AB